Administrative correction — no trading signal. Monitor next quarterly earnings and PSU vesting triggers for potential insider selling after vesting dates.
Price Chart
Executive Summary
Daniel Faga, President and CEO of First Tracks Biotherapeutics, filed this 3/A on August 7, 2026 to amend his initial beneficial ownership report (originally filed April 20, 2026). The amendment adds 53,334 performance stock units (PSUs) that were omitted from the original filing — these PSUs vest in equal tranches on March 12, 2027 and March 12, 2028, contingent on continuing service. This is a routine corrective administrative filing with no trading or economic content for equity holders.
Key Facts
- Filing amends Form 3 originally filed April 20, 2026
- Adds 53,334 performance stock units (PSUs) held by CEO Daniel Faga
- PSUs vest 50% on March 12, 2027 and 50% on March 12, 2028, subject to continued employment
- Underlying common stock equivalent is 53,334 shares
- No dollar amounts or financial metrics disclosed
- No changes to previously reported beneficial ownership totals beyond the PSU addition
Financial Impact
No financial data in filing. PSU grant of 53,334 shares represents less than 0.5% of 1.6B market cap at implied ~$30/share — de minimis dilution.
Risk Factors
- No material risks identified from this filing
- PSU vesting could lead to modest insider selling after 2027/2028 vesting
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3/A Filing (Primary) | 0001673528-26-000015 |
| Document: 0001673528-26-000015-index.html | 0001673528-26-000015 |
| Document: 0001673528-26-000015.txt | 0001673528-26-000015 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | S-1 | $43.80 | awaiting T+1 | — | $44.05 (+0.57%) |
Oct 20, 2026 5d ago | 8-K | $42.77 $43.14 | ▲ +0.87% | ▲ +2.05% | $44.05 (+2.99%) |
Oct 15, 2026 10d ago | 8-K | $34.46 $36.28 | ▼ −5.28% | ▼ −4.86% | $44.05 (−27.83%) |
Oct 15, 2026 11d ago | Press Release | $36.04 $34.46 | ▲ +4.38% | ▲ +3.28% | $44.05 (−22.23%) |
Oct 13, 2026 13d ago | 8-K | $31.68 $34.13 | ▲ +7.73% | ▲ +8.81% | $44.05 (+39.05%) |
Aug 12, 2026 10w ago | 8-K | $44.03 $44.04 | ▲ +0.02% | ▲ +0.22% | $44.05 (+0.05%) |
Aug 12, 2026 10w ago | Press Release | $44.03 $44.04 | ▲ +0.02% | ▲ +0.22% | $44.05 (+0.05%) |
Aug 7, 2026 11w ago | 3/A | $47.92 $46.75 | ▼ −2.44% | ▼ −2.12% | $44.05 (−8.08%) |
Jun 22, 2026 17w ago | 8-K | $17.78 $16.69 | ▼ −6.13% | ▼ −6.08% | $44.05 (+147.75%) |
May 14, 2026 23w ago | 8-K | $16.90 $17.79 | ▲ +5.27% | ▲ +5.33% | $44.05 (+160.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers